Los Angeles-based Cedars-Sinai Health Sciences University co-developed an AI platform that can predict which of two approved chemotherapy regimens for advanced pancreatic cancer is likely to be more effective for a given patient.
The platform analyzes scanned images of standard tumor biopsy slides, according to a March 3 news release from Cedars-Sinai. Researchers evaluated tissue samples from 25,000 pancreatic cancer patients who received one of the two chemotherapy options and examined more than 30,000 tissue features to match characteristics with treatment response.
In the study, published Feb. 11 in Journal of Clinical Oncology, the tool accurately predicted each patient’s response to the therapy they received. Unlike traditional biomarker testing, the approach requires only a digital image of an existing biopsy slide rather than additional blood or tissue samples.
Investigators said the platform could eventually be applied to other solid tumor types and to compare different treatment modalities, including chemotherapy, radiation therapy and surgery.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
